Goal hub

Sexual Health & Libido Restoration

PT-141 is Vyleesi for premenopausal HSDD. Kisspeptin is upstream GnRH biology. This page maps the SKUs. It is not a PDE5 and not a general ED or libido NDA.

Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.

Open full protocolAll goals

Compounds on this goal

PT-141

sexual_health

FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women. RECONNECT (n=1,247) is that file. A research cake is not the labeled product.

Open peptide leaf →

Kisspeptin

sexual_health

KISS1R agonist upstream of GnRH. Academic infusion papers exist. Not a TRT replacement and not Vyleesi.

Open peptide leaf →

Evidence note on this goal

Protocol evidence level (from existing goal data): Strong

  • Vyleesi FDA approval is specifically for premenopausal women with acquired HSDD; use in men is off-label
  • Maximum recommended frequency: 1 dose/24 hours, 8 doses/month to limit cardiovascular effects
  • If no benefit after 8 weeks of use, discontinuation is recommended per FDA labeling
  • Kisspeptin human sexual health data is primarily from academic research settings; not yet approved for clinical use